Ramon Martinez
Endocrinology, Diabetes & Metabolism · Pembroke Pines, FLNPI 1528122918
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,160 of the $14,570 with a category attached, or 76.6%. Teva Pharmaceuticals USA, Inc. accounts for 70.5% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $10,608, 3.8 times the $2,756 reported in 2019.
Across 147 payments — averaging $99.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$10K
- OPKO Pharmaceuticals, LLC$2K
- Sanofi-aventis U.S. LLC$313
- Neurocrine Biosciences, Inc.$270
- Boehringer Ingelheim$218
- Novo Nordisk$165
- plus $2K from 28 others
What the payments were for
- Consulting fees$4603%
- Speaking & faculty fees$11,16077%
- Food & beverage$2,95020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $10,269 |
| OPKO Pharmaceuticals, LLC | 2 | $1,500 |
| Sanofi-aventis U.S. LLC | 16 | $313 |
| Neurocrine Biosciences, Inc. | 14 | $270 |
| Boehringer Ingelheim | 11 | $218 |
| Novo Nordisk | 9 | $165 |
| Abbott | 8 | $157 |
| AstraZeneca | 7 | $147 |
| Lilly USA, LLC | 10 | $143 |
| Insulet Corporation | 7 | $137 |
| Livanova USA, Inc. | 1 | $120 |
| Shire North American Group Inc | 1 | $119 |
| Johnson & Johnson | 6 | $103 |
| Cequr Corporation | 4 | $103 |
| Merck | 6 | $102 |
| Sunovion Pharmaceuticals Inc. | 1 | $98 |
| Amgen | 6 | $86 |
| AbbVie(2 entities) | 5 | $73 |
| Corcept Therapeutics | 3 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $50 |
| BETA Bionics, Inc. | 6 | $45 |
| Mannkind Corporation | 1 | $44 |
| Amneal Pharmaceuticals LLC | 3 | $40 |
| Vanda Pharmaceuticals Inc. | 2 | $39 |
| Radius Health, Inc. | 2 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $21 |
| Halozyme Inc | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $16 |
| Theratechnologies Inc. | 1 | $16 |
| Valeritas, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$10,269
- Rayaldee$1,500
- VNS Therapy Symmetry Model 8103 Generator$120
How this compares
$14,570 in reported general payments places this provider in the 75th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 15 | $19,744 |
| MounjaroTirzepatide | 16 | $14,513 |
| JardianceEmpagliflozin | 11 | $10,082 |
| TrulicityDulaglutide | 11 | $9,317 |
| Metformin Hcl | 21 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $143 | $23,83027 claims |
| Novo NordiskOzempic | $165 | $19,74415 claims |
| Boehringer IngelheimJardiance | $218 | $10,08211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Pembroke Pines
- Fidel HenriquezPembroke Pines$548K
- Andres HenriquezPembroke Pines$136K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.